On November 5, 2024, Health Canada released the Notice to industry: Aligned reviews between Health Canada and health technology assessment organizations. According to the notice, effective immediately, the option for aligned reviews for Health Canada with health technology assessment organizations (HTAs), i.e., Canada’s Drug Agency (CDA) and l'Institut national d'excellence en santé et en services sociaux (INESSS), is available to all biological and pharmaceutical new drug submissions. The goals of aligned reviews are to reduce duplication and time lags between Health Canada market authorization and HTA recommendations, where possible.
The notice formalizes the timelines, process, and considerations for sponsors with qualifying drug submissions. Sponsors may opt in to the aligned review pathway at any stage. To do so, a sponsor must submit to Health Canada a completed consent letter template authorizing sharing of information.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and life sciences regulatory law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Health Canada seeks input on new draft guidance for co-packaged drug products
On March 18, 2025, Health Canada released a Notice that it is seeking feedback on a draft guidance on co-packaged drug products.Read More -
Canada’s Drug Agency releases 2025 Watch List highlighting AI technologies in health care
On March 25, 2025, Canada’s Drug Agency published its annual Watch List, which identifies technologies with the most potential to transform health systems and shape the future of health care in Canada...Read More -
Health Canada publishes Guide to the precision regulating authorities under the Food and Drugs Act
In March 2025, Health Canada published a Guide to the precision regulating authorities under the Food and Drugs Act.Read More